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Abstract. Smad4 is a critical regulator of transforming growth
factor (TGF)‑β signaling and is defective in numerous human
cancers. In total, 30% of pancreatic cancers harbor a homozygous deletion of Smad4. The human pancreatic cancer cell line,
BxPC3, has been reported to be Smad4‑null due to a homozygous deletion and has been widely used as a Smad4‑null
model. The present study reports that Smad4 DNA is present in
BxPC3 cells, and under conditions of suppressed mammalian
target of rapamycin complex 1 (mTORC1) and phosphatidylinositol‑3‑kinase, a truncated Smad4 protein is expressed.
While a high level of Smad4 protein can be expressed in these
cells, the cells do not respond to TGF‑β. The Smad4 defect in
BxPC3 cells likely occurs via translocation rather than deletion
as previously reported.
Introduction
Smad proteins are intracellular mediators of transforming
growth factor‑β (TGF‑β) and bone morphogenetic protein
signaling pathways necessary for the regulation of a variety of
critical processes, including embryonic development, fibrosis,
tumor development, immune function and wound healing (1,2).
Genomic sequencing has revealed numerous defects in the
TGF‑β signaling pathway of human pancreatic cancers (3).
Smad4, also known as DPC4 (deleted in pancreatic carcinoma,
locus 4), was first isolated and identified in pancreatic cancer on
human chromosome 18q21.1 (4). Hahn et al reported that ~90%
of human pancreatic cancers show allelic loss at chromosome
18q. Deletion of chromosome 18q, which encompasses the
Smad4 region, significantly affects the prognosis of pancreatic
cancer (4). Individuals with pancreatic cancer positive for
Smad4 have shown a higher survival rate compared with those

Correspondence to: Professor David A. Foster, Department of
Biological Sciences, Hunter College of The City University of New
York, 695 Park Avenue, New York, NY 10065, USA
E‑mail: foster@genectr.hunter.cuny.edu
*

Contributed equally

Key words: Smad4, pancreatic cancer, chromosomal instability,
BxPC3 cells, transforming growth factor‑β

with pancreatic cancers negative for Smad4 (5). These findings
indicate that the presence of Smad4 is critical in the development and treatment of human pancreatic cancers.
Chromosomal deletions occur in a number of cancers
causing either the absence of the gene or loss of its function (6).
According to the National Human Genomic Research Institute
and the National Center for Biotechnology Information, translocation is defined as a type of chromosomal abnormality in
which a chromosome breaks and a portion of it reattaches to
a different chromosome. Studies have shown that >90% of
human cancers possess a certain type of clonal cytogenetic
change (6‑8). The most widely described chromosomal abnormality involving chromosomal translocation is the Philadelphia
chromosome (9,10). Produced from the fusion of chromosome 9
and a truncated chromosome 22, the Philadelphia chromosome
leads to an oncogenic BCR‑ABL gene, which is responsible
for the development of chronic myelogenous leukemia (11‑14).
Thus, chromosomal translocations can lead to the formation of
new genes caused by the merging or ablation of existing genes
that contribute to the oncogenic phenotype.
Characterizing translocated genes involves the use
of banding techniques originally described by Rowley in
1973 (10). However, studies used to identify homozygous deletions on chromosome 18q in pancreatic cancer cells utilized
PCR‑based assays that focused mainly on characterizing a
specific region of chromosome 18q where homozygous deletions commonly occur, 18q21.1 (4,6). While deletion mapping
can identify missing areas of a chromosome, in the case of
Smad4 in BxPC3 cells, it does not take into consideration
deletion due to translocation. While investigating the synthetic
lethal interactions between the inhibition of as mammalian target of rapamycin complex 1 (mTORC1) and TGF‑β
signaling pathways in Smad4‑null BxPC3 cells, the expression
of a Smad4‑like protein was identified. The present study
therefore investigated whether the Smad4 gene is actually
present in BxPC3 cells, a pancreatic cancer cell line widely
used to represent a Smad4‑null genotype.
Materials and methods
Cell lines and cell culture conditions. The BxPC3 and Panc1
cells used in this study were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and
were maintained in Roswell Park Memorial Institute (RPMI)
medium and Dulbecco's modified Eagle's medium (DMEM),
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respectively, supplemented with 10% fetal bovine serum
(Hyclone, Waltham, MA, USA). BxPC3 cells were also obtained
from a stock maintained by Dr Murray Korc (University of
Indiana, Indianapolis, IN, USA). For transfection of siRNA,
the cells were plated at a density of 105 cells/60‑mm plate
24 h prior to transfection. All transfections were performed
using Lipofectamine 2000 (Gibco‑BRL, Carlsbad, CA, USA)
according to the manufacturer's instructions.
Materials. Rapamycin was obtained from LC Laboratories
(Woburn, MA, USA). The phosphatidylinositol‑3‑kinase (PI3K)
inhibitor, LY294002, and Wortmannin were obtained from
Cell Signaling Technology, Inc. (Danvers, MA, USA). Total
Smad2 (product number 5339S, monoclonal rabbit IgG), total
Smad3 (product number 9523P, monoclonal rabbit IgG) and
Smad4 (product number 9515, monoclonal rabbit IgG) primary
antibodies were obtained from Cell Signaling Technology,
Inc. (Danvers, MA, USA), and the glyceraldehyde 3‑phosphate dehydrogenase antibody was obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Smad4 siRNA and
non‑targeted negative control siRNA duplexes were obtained
from Santa Cruz Biotechnology Inc. Smad4 primers were
designed and synthesized by IDT (Coralville, IA, USA). A
DNeasy Blood and Tissue kit was obtained from Qiagen (Hilden,
Germany) and a Phusion High Fidelity DNA Polymerase kit
was obtained from New England Biolabs (Ipswich, MA, USA).
Western blot analysis. Proteins were extracted from cultured
cells in modified radioimmunoprecipitation assay buffer
(Upstate Biotechnology Inc., Lake Placid NY, USA). Equal
amounts of protein were subjected to SDS‑PAGE separating
gels. Electrophoresed proteins were then transferred to nitrocellulose and subjected to western blot analysis as described
previously (15). The results of the western blot analysis were
quantified using ImageJ software version 1.47 (NIH, Bethesda,
MD, USA)
PCR. Genomic DNA was extracted from the cells using the
Qiagen DNeasy Blood and Tissue kit. PCR amplification was
performed using primers specific to Smad4 DNA and the Phusion
High Fidelity DNA Polymerase kit was used to determine the
presence of Smad4 in each cell line. Exon 1: Forward primer,
5'‑ATGCTCAGTGGCTTCTCGACAAGTTG‑3' and reverse
primer, 3'‑GGGCTTTTTAAAGCCTCTGCACCAG‑5'.
Exon 2: forward primer, 5'‑CCTTGCAACGTTAGCTGT TGT‑3'
and reverse primer, 3'‑TGAAGCCTCCCATCCAATGTT
CTC‑5'. Exon 12: forward primer, 5'‑GTTGATGTGGATACT
TTTCACACCG‑3' and reverse primer, 3'‑CTACCACAAAGC
TGGCCTCTACCA‑5'.
Smad4 siRNA duplexes. Smad4 siRNA (human) is a pool
of three different siRNA duplexes: Exon from nucleic
acids 788‑962, with sense, GCAUCGACAGAGACAUACAtt,
and antisense, UGUAUGUCUCUGUCGAUGCtt. Exon from
nucleic acids 2277‑3086, with sense, GAUGACUGUUGAUGA
AGUAtt, and antisense, UACUUCAUCAACAGUCAUCtt.
Exon f rom nucleic acids 2277‑3086, with sense,
CAAGGUUGGUUGCUAAGAAtt and antisense, UUCUUA
GCAACCAACCUUGtt. All sequences are provided in 5'→3'
orientation.

Results
PI3K and mTOR complex 1 (mTORC1) inhibition induces expres‑
sion of Smad4 in BxPC3 cells. Defects in TGF‑β signaling have
been reported for the majority of pancreatic cancers, with deletions or mutations in Smad4 being most prevalent (3,4). Smad4 is
a member of the Smad family and plays a pivotal role in mediating
the downstream effects of the TGF‑β signaling pathway (16,17).
As a tumor suppressor, Smad4 regulates TGF‑β‑mediated epithelial cell growth or inhibition (18). Rapamycin has been reported
to activate TGF‑β signaling by mediating the nuclear translocation of activated Smad2/3 in complex with Smad4, while having
no effect on the total protein levels (19). Rapamycin has also
been reported to induce a negative feedback loop that activates
the PI3K signaling pathway, which can block the expression
and activation of Smad3, thus inhibiting the TGF‑β signaling
pathway (20). The present study therefore aimed to determine
the effect of rapamycin on Smad2, Smad3 and Smad4 protein
levels in Panc1 and BxPC3 cells. Data shown in Fig. 1A indicate
that rapamycin alone or in combination with the PI3K inhibitor,
LY294002, does not affect the expression levels of Smad2, 3 or 4
in Smad4 wild‑type Panc1 cells. Sole treatment with rapamycin
also does not affect the Smad2, 3 or 4 protein levels in BxPC3
cells; expression of Smad4 protein was not expected given the
previously reported absence of Smad4 DNA in BxPC3 cells (4).
As expected, Smad4 protein was not detected in the BxPC3
cells (Fig. 1B, left panel). However, upon dual treatment with
rapamycin and the PI3K inhibitor, LY294002, or Wortmannin
in the BxPC3 cells, a protein recognized by a Smad4 primary
antibody was expressed (Fig. 1B, middle and right panels). This
treatment had no effect on the level of Smad2 or Smad3 in the
BxPC3 cells. These data indicate that under conditions where
mTORC1 and PI3K signaling pathways are inhibited, a protein
containing a similar amino acid sequence to that of wild‑type
Smad4 is expressed in BxPC3 cells.
siRNA for Smad4 decreases the Smad4‑like protein in BxPC3
cells. The present study showed that Smad4 is detected under
stress conditions in BxPC3 cells (Fig. 1). To further confirm that
the protein expressed upon dual inhibition of the mTORC1 and
PI3K signaling pathways in BxPC3 cells is Smad4, Panc1 and
BxPC3 cells were pretreated with Smad4 siRNA followed by
dual treatment with rapamycin and LY294002. Data in Fig. 2
show that Smad4 siRNA inhibits the expression of Smad4 in
Panc1 cells (Fig. 2A), as well as the stress‑induced Smad4‑like
protein in BxPC3 cells (Fig. 3B). The human Smad4 siRNA
is a pool of three different siRNA duplexes, one from nucleic
acids 788‑962 (exon 3) and two from nucleic acids 2277‑3086
(exon 12). Therefore, this data indicates that the abrogated expression of Smad4 in BxPC3 cells is linked to the siRNA duplexes
that target either the exon 3 or 12 region of Smad4 DNA. Repeat
experiments performed on the BxPC3 cells obtained from Dr
Murray Korc showed the same pattern (data not shown).
Smad4 DNA is amplified in exon 12 of BxPC3 pancreatic cancer
cells. Proteins are generated via transcription and then translation from the subsequent DNA sequence. Therefore, proteins
cannot be made without the presence of the corresponding DNA
sequence. It has been previously reported that Smad4 DNA is
amplified in Panc1 but not BxPC3 cells (4,21). It is important
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Figure 1. PI3K and mTORC1 inhibition induces expression of Smad4 in BxPC3 cells. (A) Panc‑1 cells were plated at 105 cells/60‑mm plate in 10% serum.
(A) After 24 h, the cells were shifted to media containing 10% serum with the indicated concentration of rapamycin (Rapa) (A, left panel). After another 4 h, the
levels of Smad4, Smad2, Smad3 and GAPDH were analyzed by western blotting. Panc‑1 cells were plated at 105 cells/60‑mm plate in 10% serum. After 24 h,
the cells were shifted to media containing 10% serum and LY294002 (50 µM) for 1 h (A, right panel). The cells were then treated with the indicated concentration of Rapa. After another 4 h, the levels of Smad4, Smad2, Smad3 and GAPDH were analyzed by western blotting. (B) BxPC3 cells were plated as above
and treated with the indicated concentrations of Rapa for 4 h (left panel) or LY294002 (50 µM; middle panel) or Wortmannin (1 µM; right panel) for 1 h. Cells
initially treated with LY294002 or Wortmannin were then treated with the indicated concentration of Rapa. After 4 h, the levels of Smad4, Smad2, Smad3 and
GAPDH were analyzed by western blotting. Western blots are representative of at least three independent experiments. PI3K, phosphatidylinositol‑3‑kinase;
GAPDH, glyceraldehyde 3‑phosphate dehydrogenase; mTORC1, mammalian target of rapamycin complex 1.
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Figure 2. siRNA for Smad4 decreases the Smad4‑like protein in BxPC3 cells. (A) Panc‑1 cells were plated in media containing 10% serum for 24 h. The cells were
then transfected with either control or Smad4 siRNA. After 48 h, the Panc1 cells were placed in fresh media containing 10% serum and LY294002 (50 µM) for 1 h,
then rapamycin (Rapa; 20 µM) for 4 h at the indicated concentrations. The total lysate was analyzed by western blotting for levels of Smad4, Smad2, Smad3 and
GAPDH. Western blots are representative of at least two independent experiments. (B) BxPC3 cells were plated in media containing 10% serum for 24 h. The cells
were then transfected with either control or Smad4 siRNA. After 24 h, the BxPC3 cells were placed in fresh media containing 10% serum and LY294002 (50 µM)
for 1 h, then Rapa (20 µM) for 4 h at the indicated concentrations. The cells were then collected, lysed and analyzed by western blotting for levels of Smad4, total
Smad2, total Smad3 and GAPDH. Western blots are representative of at least two independent experiments. GAPDH, glyceraldehyde 3‑phosphate dehydrogenase.
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Figure 3. Smad4 DNA is amplified in exon 12 of BxPC3 pancreatic cancer cells. (A) Schematic of Smad4 gene. (B) Panc1 and BxPC3 cells were plated at a density
of 105 cells/60‑mm plate. After 24 h, the cells were provided with fresh media containing 10% serum, and DNA from the Panc1 and BxPC3 cells was extracted using
a Quigen DNA extraction kit. The acquired DNA was analyzed by PCR. PCR analyses are representative of at least two independent experiments. (C) BxPC3 cells
were plated as stated above and then shifted to media containing 10% serum and LY294002 (50 µM) or Wortmannin (1 µM) for 1 h. The cells were then treated with
the indicated concentration of rapamycin (Rapa). After 4 h, the levels of Smad4 were analyzed by western blotting. Panc‑1 was used as a positive control.

to note that Smad4 DNA contains 12 exons, which encode for
the 552‑amino acid Smad4 protein; exon 12 being the largest,
measuring 6.787 kb (Fig. 3A) (22). Therefore, to determine the
source of the inducible Smad4 protein in the BxPC3 cells, DNA
extracted post‑treatment with rapamycin and LY294002 was

analyzed by PCR. Exon 1 of Smad4 has been previously used
to identify the presence or absence of the gene (4). As shown
in Fig. 3B, DNA was amplified in the Panc1 cells for exon 1,
2 and 12, the largest primer derived exons, in the presence of
serum. However, when analyzing the BxPC3 cells, a DNA
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amplification band was only observed for exon 12 (Fig. 3B).
Given that only the Smad4 DNA fragment corresponding to
exon 12 is present in BxPC3 cells, it is possible that the protein
expressed post‑treatment with rapamycin and the PI3K inhibitors is a truncated form of Smad4. As with the Philadelphia
chromosome, depending on the precise translocated region of
the Smad4 gene, the molecular weight of the corresponding
protein can be altered (14). Therefore, to determine the relative
size of Smad4 expressed in the BxPC3 cells, the cells that were
dually treated with high‑dose rapamycin and LY294002 or
Wortmannin were analyzed for Smad4 on the same western blot
gel using Panc‑1 cells as a positive control. As shown in Fig. 3C,
Smad4 in the BxPC3 cells had a slightly faster electrophoretic
mobility than wild‑type Panc‑1 Smad4. Taken together, these
data indicate that BxPC3 cells express an inducible truncated
version of the Smad4 protein, encoded mostly in exon 12 of
Smad4 DNA.
Discussion
BxPC3 cells are reported to have a homozygous deletion on
chromosome 18q, which encompasses the coding region for
Smad4/DPC4, 18q21.1 (4). PCR‑assays, along with the combination of deletion and physical mapping, were employed to
identify the homozygous deleted regions of chromosome 18q
and resulted in the identification of Smad4 as a tumor
suppressor located at chromosome 18q21.1 (4,6). Hahn et al
reported that chromosomal region 18q21.1 is deleted in 30%
of pancreatic cancers, including in BxPC3 cells. Homozygous
deletion of Smad4 has been correlated with the loss of expression of the corresponding protein (23). Smad4 plays a pivotal
role in regulating TGF‑β signaling and can function as a tumor
suppressor or promoter (5,24).
The homozygous loss of Smad4 has been the basis for use
of BxPC3 cells as a model for pancreatic cancer with defective TGF‑β signaling. We previously reported that TGF‑β was
unable to rescue BxPC3 cells from rapamycin‑induced cell
death, as was the case in the Smad4 wild‑type Panc1 pancreatic
cancer cells (15) indicating that BxPC3 pancreatic cancer cells
are not responsive to TGF‑β. However, in the present study, we
suggest that the basis for defective TGF‑β signaling in BxPC3
cells is not due to the homozygous deletion of Smad4, in that
much of the Smad4 gene is present and expressed in response
to the stress of mTORC1 and PI3K suppression. Thus, it is more
likely that the loss of the Smad4 gene on chromosome 18q is due
to a translocation rather than homozygous deletion. Whether the
truncated Smad4 protein has any phenotypic impact on BxPC3
cells is not known, however, it appears that BxPC3 cells do not
respond to TGF‑β.
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